Search
Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigational[L46342,L46387] Later on, the FDA approved pegunigalsidase alfa for the treatment of adult patients with Fabry disease that same month.[L46432,L46437] … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular
Birch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational[L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023.
Belumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines
Xenon Xe-129
go.drugbank.com/drugs/DB17386ApprovedInvestigational[A255183] In December 2022, the FDA approved the use of hyperpolarized Xe-129 for use with MRI for the evaluation of lung ventilation.
Isosorbide mononitrate
go.drugbank.com/drugs/DB01020ApprovedInvestigational[T28] First approved by the FDA in 1991,[L11743] isosorbide mononitrate is used for the prevention and management of angina pectoris caused by coronary artery disease; however, the onset of action of
Asciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigational[L38995,A241055] Asciminib received FDA approval on October 29, 2021 (Scemblix, Novartis AG).[L39000]
Oteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[L41635] This drug was approved by the FDA on April 26, 2022.[L41645]
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.
Ensartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A265030] Ensartinib was approved by the FDA for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously
Maropitant
go.drugbank.com/drugs/DB11427ExperimentalVet approvedIt was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.